Add to a list

Inactive Instrument

LOTUS PHARM Share Price OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

31/23/31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/21/26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	97.36L 86.76L 80.32L 72.69L 1.37Cr 92Cr 1.39Cr 9.63Cr 3.78Cr 48Cr 3.65Cr 3.58Cr 153.88Cr	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	1.44Cr 1.28Cr 1.19Cr 1.07Cr 2.02Cr 135.72Cr 2.05Cr 14Cr 5.58Cr 71Cr 5.4Cr 5.28Cr 227.33Cr	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

31/23/31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/21/26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/21/28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/12/16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/12/19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

30/12	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/25/06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/25/12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
21/25/21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/24/08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+3.58%	+4.87%	+61.56%	+127.62%	1,13300Cr
JOHNSON & JOHNSON	+3.00%	+4.51%	+37.20%	+74.86%	62TCr
ABBVIE INC.	-0.23%	+0.52%	+24.57%	+96.82%	50TCr
ROCHE HOLDING AG	-0.41%	+2.79%	+39.14%	+64.30%	38TCr
MERCK & CO., INC.	+1.72%	+5.26%	+74.44%	+47.88%	37TCr
NOVARTIS AG	+1.92%	+2.54%	+23.12%	+52.78%	29TCr
ASTRAZENECA PLC	+2.51%	+1.64%	+2.92%	+27.78%	26TCr
AMGEN INC.	+2.35%	+3.39%	+51.61%	+64.34%	24TCr
GILEAD SCIENCES, INC.	+1.47%	-0.73%	+28.62%	+101.42%	19TCr
Average	+1.80%	+3.22%	+38.13%	+73.09%	44.31TCr
Weighted average by Cap.	+2.15%	+3.73%	+43.32%	+85.04%

	2009	2010
Net sales	5.78Cr 5.15Cr 4.77Cr 4.32Cr 8.13Cr 545.67Cr 8.23Cr 57Cr 22Cr 286.82Cr 22Cr 21Cr 913.98Cr	7.27Cr 6.48Cr 6Cr 5.43Cr 10Cr 686.01Cr 10Cr 72Cr 28Cr 360.59Cr 27Cr 27Cr 1.15TCr
Net income	1.64Cr 1.46Cr 1.36Cr 1.23Cr 2.31Cr 155.07Cr 2.34Cr 16Cr 6.38Cr 82Cr 6.16Cr 6.04Cr 259.73Cr	1.44Cr 1.29Cr 1.19Cr 1.08Cr 2.03Cr 136.12Cr 2.05Cr 14Cr 5.6Cr 72Cr 5.41Cr 5.3Cr 228Cr
Net Debt	5.29 4.72 4.37 3.95 7.45 499.56 7.53 52.37 20.55 262.59 19.86 19.45 836.75	4.65 4.14 3.83 3.47 6.54 438.5 6.61 45.96 18.04 230.49 17.43 17.07 734.47

LOTUS PHARM Share Price OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile